Investors Encouraged to Act on Iovance Biotherapeutics Class Action by Kahn Swick & Foti

Iovance Biotherapeutics Class Action Lawsuit Alert

In recent developments regarding Iovance Biotherapeutics, Inc. (NasdaqGM IOVA), Kahn Swick & Foti, LLC, along with Charles C. Foti, Jr., the former Attorney General of Louisiana, is calling attention to a significant investor opportunity. Investors who have incurred losses exceeding $100,000 between May 9, 2024, and May 8, 2025, have a deadline approaching for joining a class action lawsuit against the company. The deadline for filing applications to serve as lead plaintiff is set for July 15, 2025.

What Happened?

Iovance and some of its executives have been accused of not disclosing essential information during the specified Class Period, which is purported to violate federal securities laws. This announcement follows the company's recent disclosure of disappointing financial results for the first quarter of 2025. Specifically, Iovance reported a total product revenue of just $49.3 million, significantly reduced from the previous quarter's $73.7 million. Compounding this disappointment, the company slashed its guidance for total product revenue for the fiscal year 2025 from a range of $450 million to $475 million down to only $250 million to $300 million.

The revision in financial expectations was attributed to the dynamics surrounding the launch of their product, Amtagvi, as well as considerations of growth trajectories and treatment timelines in the authorized treatment centers (ATCs).

Despite these challenges, the announcement caused Iovance's stock to tumble by nearly 44.8%, dropping from $1.42 to $1.75 just a day later on May 9, 2025, an indication of the volatility surrounding the company’s stock and investors' sentiments.

The Legal Action

The case filed against Iovance is known as Farberov v. Iovance Biotherapeutics, Inc., et al., and is currently pending in the United States District Court for the Northern District of California. Investors are encouraged to reach out to Kahn Swick & Foti to discuss their legal rights and to understand how this case might have implications for their financial recovery. KSF has offered a no-obligation consultation to those who need assistance in determining their next steps.

How to Get Involved

For investors who wish to engage in this legal process and potentially recover losses due to alleged securities violations, reaching out to the law firm is critical. To become a lead plaintiff, applicants will need to petition the court before the July 15 deadline. Interested parties can contact KSF’s Managing Partner Lewis Kahn by calling 1-877-515-1850 or through email at info@ksfcounsel.com. More information can also be found on their website at Kahn Swick & Foti.

About Kahn Swick & Foti, LLC

As a recognized name in securities litigation, KSF has built a reputation for advocating on behalf of both institutional and retail investors. The firm is designed to pursue recoveries stemming from financial misconduct and has been ranked among the top litigation firms nationally for the past years. With offices spanning locations such as New York, California, Louisiana, and Luxembourg, KSF continues to position itself as a leader in investor advocacy.

For any investor affected by recent developments with Iovance Biotherapeutics, now is the time to engage and understand your rights and potential avenues for recovery.